_open-orphan-world39s-first-covid-19-characterisation-study.jpg "Open Orphan world's first COVID-19 characterisation study from orph Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 86 sec
✓ Published: 03-Feb-2022
✓ Published: 03-Feb-2022
Description:
Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world's first COVID-19 characterisation study.nnCathal explains what these results mean for Open Orphan, plans to initiate the next phase of the Human Challenge Programme, studies to approve new vaccines and antivirals and with 95% of 2022 targeted revenues contracted being non-Covid revenue can we expect some COVID-19 revenue this year.
Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world's first COVID-19 characterisation study.nnCathal explains what these results mean for Open Orphan, plans to initiate the next phase of the Human Challenge Programme, studies to approve new vaccines and antivirals and with 95% of 2022 targeted revenues contracted being non-Covid revenue can we expect some COVID-19 revenue this year.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_open-orphan-39expect-some-quite-substantial-contracts39.webp "Open Orphan (LON:ORPH) CEO Cathal Friel joins DirectorsTalk to discuss the testing of an anti-viral for treating COVID-19. Cathal explains whats involved in the testing, the time frames involved and what investors should expect over the coming months and weeks.")
_open-orphan-plc-coronavirus-challenge-study-model.webp "Open Orphan (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk to discuss the commencement of development of world’s first commercial human coronavirus challenge study model. Cathal provides us with more details on the study, explains how this will be funded and the timelines expected for the study.")
_open-orphan-investor-presentation-march-2022.webp "Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation.nnOpen Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.nnFor all the latest Open Orphan share price, news and interviews take a look at the company profile page. nnhttps://www.directorstalkinterviews.com/open-orphan-plc/orph.l")
_desejos-para-2017-prefeitura-de-cotipor.webp "Cotiporã | Rio Grande do Sul | ORPHdrones.comnnResultado de uma parceria entre Prefeitura de Cotiporã, ORPHdrones e Maísa Marson Foto e Arte, sobre os desejos da comunidade para o ano de 2017. Felicidade e emoção são as sensações mais presentes neste trabalho.")
_em-2018-recomece.webp "Cotiporã | Rio Grande do Sul | ORPHdrones.comnnO que queremos para 2018? Este trabalho é resultado de uma parceria entre Prefeitura Municipal de Cotiporã e ORPHdrones.")
_open-orphan-rsv-human-challenge-study.webp "Open Orphan (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk to discuss the signing of a new contract with a European Biotech Company for the provision of a RSV human challenge study. Cathal explains what the study entails, what it means for the company, the timescales involved and what else is going on in the company.")
_blackorph.webp "BlackOrph from orph")
_hanorphwaspanimaticvid.webp "HanOrphWaspAnimaticVid from orph")
_open-orphan-39expect-some-quite-substantial-contracts39.jpg)
_open-orphan-plc-coronavirus-challenge-study-model.jpg)
_open-orphan-investor-presentation-march-2022.jpg)
_desejos-para-2017-prefeitura-de-cotipor.jpg)
_em-2018-recomece.jpg)
_open-orphan-rsv-human-challenge-study.jpg)
_blackorph.jpg)
_hanorphwaspanimaticvid.jpg)
![[+]](/images/menu.gif){kind=small}